{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:38:34Z","timestamp":1786981114184,"version":"build-2736575974"},"reference-count":122,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T00:00:00Z","timestamp":1746230400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T00:00:00Z","timestamp":1746230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-025-03535-0","type":"journal-article","created":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T06:28:50Z","timestamp":1746253730000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Thyroid-related orbitopathy: clinical overview, novel medical treatments and the role of orbital surgery"],"prefix":"10.1007","volume":"45","author":[{"given":"Federico","family":"Giannuzzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo Mario","family":"Carl\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Crincoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Gambini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Boselli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Cuffaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Parrilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Rigante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica Maria","family":"Pagliara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislao","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Savino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,3]]},"reference":[{"issue":"16","key":"3535_CR1","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1056\/NEJMra1510030","volume":"375","author":"TJ Smith","year":"2016","unstructured":"Smith TJ, Heged\u00fcs L (2016) Graves\u2019 disease. N Engl J Med 375(16):1552\u20131565","journal-title":"N Engl J Med"},{"issue":"3","key":"3535_CR2","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/0026-0495(72)90041-8","volume":"21","author":"J Furszyfer","year":"1972","unstructured":"Furszyfer J, Kurland LT, McConahey WM, Woolner LB, Elveback LR (1972) Epidemiologic aspects of Hashimoto\u2019s thyroiditis and Graves\u2019 disease in Rochester, Minnesota (1935\u20131967), with special reference to temporal trends. Metabolism 21(3):197\u2013204","journal-title":"Metabolism"},{"key":"3535_CR3","first-page":"477","volume":"92","author":"GB Bartley","year":"1994","unstructured":"Bartley GB (1994) The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota. Trans Am Ophthalmol Soc 92:477\u2013588","journal-title":"Trans Am Ophthalmol Soc"},{"key":"3535_CR4","doi-asserted-by":"publisher","first-page":"1062045","DOI":"10.3389\/fimmu.2023.1062045","volume":"14","author":"X Cui","year":"2023","unstructured":"Cui X, Wang F, Liu C (2023) A review of TSHR- and IGF-1R-related pathogenesis and treatment of Graves\u2019 orbitopathy. Front Immunol 14:1062045. https:\/\/doi.org\/10.3389\/fimmu.2023.1062045","journal-title":"Front Immunol"},{"issue":"1","key":"3535_CR5","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/cen.12688","volume":"84","author":"L Bartalena","year":"2016","unstructured":"Bartalena L, Burch HB, Burman KD, Kahaly GJ (2016) A 2013 European survey of clinical practice patterns in the management of Graves\u2019 disease. Clin Endocrinol (Oxford) 84(1):115\u2013120. https:\/\/doi.org\/10.1111\/cen.12688","journal-title":"Clin Endocrinol (Oxford)"},{"issue":"1","key":"3535_CR6","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13023-017-0625-1","volume":"12","author":"P Perros","year":"2017","unstructured":"Perros P, Hegedus L, Bartalena L et al (2017) Graves\u2019 orbitopathy as a rare disease in Europe: a European Group on Graves\u2019 Orbitopathy (EUGOGO) position statement. Orphanet J Rare Dis 12(1):72. https:\/\/doi.org\/10.1186\/s13023-017-0625-1","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"3535_CR7","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/sj.eye.6702603","volume":"21","author":"J Thornton","year":"2007","unstructured":"Thornton J, Kelly SP, Harrison RA, Edwards R (2007) Cigarette smoking and thyroid eye disease: a systematic review. Eye (London) 21(9):1135\u20131145. https:\/\/doi.org\/10.1038\/sj.eye.6702603","journal-title":"Eye (London)"},{"key":"3535_CR8","doi-asserted-by":"publisher","first-page":"b560","DOI":"10.1136\/bmj.b560","volume":"338","author":"P Perros","year":"2009","unstructured":"Perros P, Neoh C, Dickinson J (2009) Thyroid eye disease. BMJ 338:b560. https:\/\/doi.org\/10.1136\/bmj.b560","journal-title":"BMJ"},{"issue":"6","key":"3535_CR9","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.disamonth.2014.03.010","volume":"60","author":"PO Phelps","year":"2014","unstructured":"Phelps PO, Williams K (2014) Thyroid eye disease for the primary care physician. Dis Mon 60(6):292\u2013298. https:\/\/doi.org\/10.1016\/j.disamonth.2014.03.010","journal-title":"Dis Mon"},{"key":"3535_CR10","volume-title":"Albert & Jakobiec's Principles and practice of ophthalmology","author":"DM Albert","year":"2008","unstructured":"Albert DM, Miller JW, Azar DT, Young LH (2008) Albert & Jakobiec\u2019s Principles and practice of ophthalmology. Saunders Elsevier, Philadelphia"},{"issue":"8","key":"3535_CR11","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1136\/bjo.73.8.639","volume":"73","author":"MP Mourits","year":"1989","unstructured":"Mourits MP, Koornneef L, Wiersinga WM, Prummel MF, Berghout A, van der Gaag R (1989) Clinical criteria for the assessment of disease activity in Graves\u2019 ophthalmopathy: a novel approach. Br J Ophthalmol 73(8):639\u2013644. https:\/\/doi.org\/10.1136\/bjo.73.8.639","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"3535_CR12","doi-asserted-by":"publisher","first-page":"848","DOI":"10.3390\/jpm14080848","volume":"14","author":"F Lixi","year":"2024","unstructured":"Lixi F, Cuccu A, Giannaccare G et al (2024) Subclinical ocular motility dysfunction and extraocular muscle changes in inactive Graves\u2019 orbitopathy. J Personal Med 14(8):848","journal-title":"J Personal Med"},{"key":"3535_CR13","doi-asserted-by":"publisher","first-page":"249125","DOI":"10.1155\/2015\/249125","volume":"2015","author":"J Barrio-Barrio","year":"2015","unstructured":"Barrio-Barrio J, Sabater AL, Bonet-Farriol E, Velazquez-Villoria A, Galofre JC (2015) Graves\u2019 ophthalmopathy: VISA versus EUGOGO classification, assessment, and management. J Ophthalmol 2015:249125. https:\/\/doi.org\/10.1155\/2015\/249125","journal-title":"J Ophthalmol"},{"issue":"5","key":"3535_CR14","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/01.iop.0000235499.34867.85","volume":"22","author":"PJ Dolman","year":"2006","unstructured":"Dolman PJ, Rootman J (2006) VISA classification for Graves orbitopathy. Ophthalmic Plast Reconstr Surg 22(5):319\u2013324. https:\/\/doi.org\/10.1097\/01.iop.0000235499.34867.85","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"4","key":"3535_CR15","doi-asserted-by":"publisher","first-page":"G43","DOI":"10.1530\/eje-21-0479","volume":"185","author":"L Bartalena","year":"2021","unstructured":"Bartalena L, Kahaly GJ, Baldeschi L et al (2021) The 2021 European Group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy. Eur J Endocrinol 185(4):G43-g67. https:\/\/doi.org\/10.1530\/eje-21-0479","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"3535_CR16","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1530\/EJE-07-0666","volume":"158","author":"L Bartalena","year":"2008","unstructured":"Bartalena L, Baldeschi L, Dickinson A et al (2008) Consensus statement of the European Group on Graves\u2019 orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 158(3):273\u2013285. https:\/\/doi.org\/10.1530\/EJE-07-0666","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"3535_CR17","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1089\/thy.2007.0315","volume":"18","author":"L Bartalena","year":"2008","unstructured":"Bartalena L, Baldeschi L, Dickinson AJ et al (2008) Consensus statement of the European group on Graves\u2019 orbitopathy (EUGOGO) on management of Graves\u2019 orbitopathy. Thyroid 18(3):333\u2013346. https:\/\/doi.org\/10.1089\/thy.2007.0315","journal-title":"Thyroid"},{"issue":"10 Suppl","key":"3535_CR18","first-page":"15","volume":"36","author":"C Marcocci","year":"2013","unstructured":"Marcocci C, Bartalena L (2013) Role of oxidative stress and selenium in Graves\u2019 hyperthyroidism and orbitopathy. J Endocrinol Invest 36(10 Suppl):15\u201320","journal-title":"J Endocrinol Invest"},{"issue":"20","key":"3535_CR19","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1056\/NEJMoa1012985","volume":"364","author":"C Marcocci","year":"2011","unstructured":"Marcocci C, Kahaly GJ, Krassas GE et al (2011) Selenium and the course of mild Graves\u2019 orbitopathy. N Engl J Med 364(20):1920\u20131931. https:\/\/doi.org\/10.1056\/NEJMoa1012985","journal-title":"N Engl J Med"},{"issue":"10 Suppl","key":"3535_CR20","first-page":"1","volume":"36","author":"J Kohrle","year":"2013","unstructured":"Kohrle J (2013) Pathophysiological relevance of selenium. J Endocrinol Invest 36(10 Suppl):1\u20137","journal-title":"J Endocrinol Invest"},{"issue":"9822","key":"3535_CR21","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1016\/S0140-6736(11)61452-9","volume":"379","author":"MP Rayman","year":"2012","unstructured":"Rayman MP (2012) Selenium and human health. Lancet 379(9822):1256\u20131268. https:\/\/doi.org\/10.1016\/S0140-6736(11)61452-9","journal-title":"Lancet"},{"key":"3535_CR22","doi-asserted-by":"publisher","DOI":"10.1530\/etj-24-0122","author":"H Zhang","year":"2024","unstructured":"Zhang H, Wu S, Hu S et al (2024) Prediction models of intravenous glucocorticoids therapy response in thyroid eye disease. Eur Thyroid J. https:\/\/doi.org\/10.1530\/etj-24-0122","journal-title":"Eur Thyroid J"},{"issue":"2","key":"3535_CR23","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1210\/jc.2010-1962","volume":"96","author":"S Zang","year":"2011","unstructured":"Zang S, Ponto KA, Kahaly GJ (2011) Clinical review: Intravenous glucocorticoids for Graves\u2019 orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab 96(2):320\u2013332. https:\/\/doi.org\/10.1210\/jc.2010-1962","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"3535_CR24","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1530\/EJE-11-0779","volume":"166","author":"C Marcocci","year":"2012","unstructured":"Marcocci C, Watt T, Altea MA et al (2012) Fatal and non-fatal adverse events of glucocorticoid therapy for Graves\u2019 orbitopathy: a questionnaire survey among members of the European Thyroid Association. Eur J Endocrinol 166(2):247\u2013253. https:\/\/doi.org\/10.1530\/EJE-11-0779","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"3535_CR25","doi-asserted-by":"publisher","first-page":"5234","DOI":"10.1210\/jc.2005-0148","volume":"90","author":"GJ Kahaly","year":"2005","unstructured":"Kahaly GJ, Pitz S, Hommel G, Dittmar M (2005) Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves\u2019 orbitopathy. J Clin Endocrinol Metab 90(9):5234\u20135240. https:\/\/doi.org\/10.1210\/jc.2005-0148","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"3535_CR26","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s40618-014-0227-x","volume":"38","author":"M Riedl","year":"2015","unstructured":"Riedl M, Kolbe E, Kampmann E, Kramer I, Kahaly GJ (2015) Prospectively recorded and MedDRA-coded safety data of intravenous methylprednisolone therapy in Graves\u2019 orbitopathy. J Endocrinol Invest 38(2):177\u2013182. https:\/\/doi.org\/10.1007\/s40618-014-0227-x","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"3535_CR27","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1089\/thy.2013.0445","volume":"24","author":"N Curro","year":"2014","unstructured":"Curro N, Covelli D, Vannucchi G et al (2014) Therapeutic outcomes of high-dose intravenous steroids in the treatment of dysthyroid optic neuropathy. Thyroid 24(5):897\u2013905. https:\/\/doi.org\/10.1089\/thy.2013.0445","journal-title":"Thyroid"},{"key":"3535_CR28","first-page":"3","volume":"4","author":"GE Krassas","year":"2005","unstructured":"Krassas GE, Wiersinga WM (2005) Thyroid eye disease: current concepts and the EUGOGO perspective. Thyroid Int 4:3\u201321","journal-title":"Thyroid Int"},{"key":"3535_CR29","doi-asserted-by":"publisher","first-page":"243","DOI":"10.2147\/imcrj.S164372","volume":"11","author":"DS Ismailova","year":"2018","unstructured":"Ismailova DS, Belovalova IM, Grusha YO, Sviridenko NY (2018) Orbital decompression in the system of treatment for complicated thyroid eye disease: case report and literature review. Int Med Case Rep J 11:243\u2013249. https:\/\/doi.org\/10.2147\/imcrj.S164372","journal-title":"Int Med Case Rep J"},{"issue":"7","key":"3535_CR30","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1442-9071.2010.02332.x","volume":"38","author":"AA Alkawas","year":"2010","unstructured":"Alkawas AA, Hussein AM, Shahien EA (2010) Orbital steroid injection versus oral steroid therapy in management of thyroid-related ophthalmopathy. Clin Exp Ophthalmol 38(7):692\u2013697. https:\/\/doi.org\/10.1111\/j.1442-9071.2010.02332.x","journal-title":"Clin Exp Ophthalmol"},{"issue":"11","key":"3535_CR31","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1136\/bjo.2004.046193","volume":"88","author":"R Ebner","year":"2004","unstructured":"Ebner R, Devoto MH, Weil D et al (2004) Treatment of thyroid associated ophthalmopathy with periocular injections of triamcinolone. Br J Ophthalmol 88(11):1380\u20131386. https:\/\/doi.org\/10.1136\/bjo.2004.046193","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"3535_CR32","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s00417-012-2153-y","volume":"251","author":"SJ Lee","year":"2013","unstructured":"Lee SJ, Rim TH, Jang SY et al (2013) Treatment of upper eyelid retraction related to thyroid-associated ophthalmopathy using subconjunctival triamcinolone injections. Graefes Arch Clin Exp Ophthalmol 251(1):261\u2013270. https:\/\/doi.org\/10.1007\/s00417-012-2153-y","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"3535_CR33","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1530\/acta.0.1220008","volume":"122","author":"P Perros","year":"1990","unstructured":"Perros P, Weightman DR, Crombie AL, Kendall-Taylor P (1990) Azathioprine in the treatment of thyroid-associated ophthalmopathy. Acta Endocrinol (Copenh) 122(1):8\u201312. https:\/\/doi.org\/10.1530\/acta.0.1220008","journal-title":"Acta Endocrinol (Copenh)"},{"issue":"1","key":"3535_CR34","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1530\/acta.0.1220013","volume":"122","author":"G Kahaly","year":"1990","unstructured":"Kahaly G, Lieb W, Muller-Forell W et al (1990) Ciamexone in endocrine orbitopathy. A randomized double-blind, placebo-controlled study. Acta Endocrinol (Copenh). 122(1):13\u201321. https:\/\/doi.org\/10.1530\/acta.0.1220013","journal-title":"Acta Endocrinol (Copenh)."},{"issue":"12","key":"3535_CR35","doi-asserted-by":"publisher","first-page":"5910","DOI":"10.1210\/jc.2004-0697","volume":"89","author":"AJ Dickinson","year":"2004","unstructured":"Dickinson AJ, Vaidya B, Miller M et al (2004) Double-blind, placebo-controlled trial of octreotide long-acting repeatable (LAR) in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 89(12):5910\u20135915. https:\/\/doi.org\/10.1210\/jc.2004-0697","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"3535_CR36","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1097\/ICU.0b013e3283499433","volume":"22","author":"M Kazim","year":"2011","unstructured":"Kazim M, Gold KG (2011) A review of surgical techniques to correct upper eyelid retraction associated with thyroid eye disease. Curr Opin Ophthalmol 22(5):391\u2013393. https:\/\/doi.org\/10.1097\/ICU.0b013e3283499433","journal-title":"Curr Opin Ophthalmol"},{"issue":"5","key":"3535_CR37","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.ajo.2004.09.005","volume":"138","author":"V Russo","year":"2004","unstructured":"Russo V, Querques G, Primavera V, Noci ND (2004) Incidence and treatment of diplopia after three-wall orbital decompression in Graves\u2019 ophthalmopathy. Am J Ophthalmol 138(5):901. https:\/\/doi.org\/10.1016\/j.ajo.2004.09.005","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"3535_CR38","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/BF03347943","volume":"14","author":"C Marcocci","year":"1991","unstructured":"Marcocci C, Bartalena L, Bogazzi F, Bruno-Bossio G, Lepri A, Pinchera A (1991) Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves\u2019 ophthalmopathy is more effective than radiotherapy alone: results of a prospective randomized study. J Endocrinol Invest 14(10):853\u2013860. https:\/\/doi.org\/10.1007\/BF03347943","journal-title":"J Endocrinol Invest"},{"issue":"6","key":"3535_CR39","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1210\/jcem-56-6-1139","volume":"56","author":"L Bartalena","year":"1983","unstructured":"Bartalena L, Marcocci C, Chiovato L et al (1983) Orbital cobalt irradiation combined with systemic corticosteroids for Graves\u2019 ophthalmopathy: comparison with systemic corticosteroids alone. J Clin Endocrinol Metab 56(6):1139\u20131144. https:\/\/doi.org\/10.1210\/jcem-56-6-1139","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"3535_CR40","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1210\/jcem-37-2-276","volume":"37","author":"SS Donaldson","year":"1973","unstructured":"Donaldson SS, Bagshaw MA, Kriss JP (1973) Supervoltage orbital radiotherapy for Graves\u2019 ophthalmopathy. J Clin Endocrinol Metab 37(2):276\u2013285. https:\/\/doi.org\/10.1210\/jcem-37-2-276","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"3535_CR41","doi-asserted-by":"publisher","first-page":"3857","DOI":"10.1210\/jc.2012-2758","volume":"97","author":"ML Tanda","year":"2012","unstructured":"Tanda ML, Bartalena L (2012) Efficacy and safety of orbital radiotherapy for graves\u2019 orbitopathy. J Clin Endocrinol Metab 97(11):3857\u20133865. https:\/\/doi.org\/10.1210\/jc.2012-2758","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"3535_CR42","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/s0360-3016(01)01699-6","volume":"51","author":"SD Marquez","year":"2001","unstructured":"Marquez SD, Lum BL, McDougall IR et al (2001) Long-term results of irradiation for patients with progressive Graves\u2019 ophthalmopathy. Int J Radiat Oncol Biol Phys 51(3):766\u2013774. https:\/\/doi.org\/10.1016\/s0360-3016(01)01699-6","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"3535_CR43","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1016\/j.ophtha.2003.12.054","volume":"111","author":"IM Wakelkamp","year":"2004","unstructured":"Wakelkamp IM, Tan H, Saeed P et al (2004) Orbital irradiation for Graves\u2019 ophthalmopathy: Is it safe? A long-term follow-up study. Ophthalmology 111(8):1557\u20131562. https:\/\/doi.org\/10.1016\/j.ophtha.2003.12.054","journal-title":"Ophthalmology"},{"issue":"15","key":"3535_CR44","doi-asserted-by":"publisher","first-page":"6038","DOI":"10.7150\/ijbs.103977","volume":"20","author":"H Zhang","year":"2024","unstructured":"Zhang H, Zhou Y, Yu B et al (2024) Multi-omics approaches to discover biomarkers of thyroid eye disease: a systematic review. Int J Biol Sci 20(15):6038\u20136055. https:\/\/doi.org\/10.7150\/ijbs.103977","journal-title":"Int J Biol Sci"},{"issue":"6","key":"3535_CR45","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1111\/cen.13834","volume":"89","author":"Z Sipkova","year":"2018","unstructured":"Sipkova Z, Insull EA, David J, Turner HE, Keren S, Norris JH (2018) Early use of steroid-sparing agents in the inactivation of moderate-to-severe active thyroid eye disease: a step-down approach. Clin Endocrinol (Oxf) 89(6):834\u2013839. https:\/\/doi.org\/10.1111\/cen.13834","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"3535_CR46","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S2213-8587(18)30020-2","volume":"6","author":"GJ Kahaly","year":"2018","unstructured":"Kahaly GJ, Riedl M, Konig J et al (2018) Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves\u2019 orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. Lancet Diabetes Endocrinol 6(4):287\u2013298. https:\/\/doi.org\/10.1016\/S2213-8587(18)30020-2","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3535_CR47","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.bbi.2018.09.020","volume":"75","author":"AG Mazumder","year":"2019","unstructured":"Mazumder AG, Patial V, Singh D (2019) Mycophenolate mofetil contributes to downregulation of the hippocampal interleukin type 2 and 1beta mediated PI3K\/AKT\/mTOR pathway hyperactivation and attenuates neurobehavioral comorbidities in a rat model of temporal lobe epilepsy. Brain Behav Immun 75:84\u201393. https:\/\/doi.org\/10.1016\/j.bbi.2018.09.020","journal-title":"Brain Behav Immun"},{"issue":"5","key":"3535_CR48","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/j.1365-2362.1986.tb01016.x","volume":"16","author":"G Kahaly","year":"1986","unstructured":"Kahaly G, Schrezenmeir J, Krause U et al (1986) Ciclosporin and prednisone v. prednisone in treatment of Graves\u2019 ophthalmopathy: a controlled, randomized and prospective study. Eur J Clin Invest 16(5):415\u2013422. https:\/\/doi.org\/10.1111\/j.1365-2362.1986.tb01016.x","journal-title":"Eur J Clin Invest"},{"issue":"2","key":"3535_CR49","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1097\/BOR.0000000000000000","volume":"26","author":"T Dorner","year":"2014","unstructured":"Dorner T, Lipsky PE (2014) B cells: depletion or functional modulation in rheumatic diseases. Curr Opin Rheumatol 26(2):228\u2013236. https:\/\/doi.org\/10.1097\/BOR.0000000000000000","journal-title":"Curr Opin Rheumatol"},{"issue":"11","key":"3535_CR50","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.1210\/jc.2013-1804","volume":"98","author":"M Salvi","year":"2013","unstructured":"Salvi M, Vannucchi G, Beck-Peccoz P (2013) Potential utility of rituximab for Graves\u2019 orbitopathy. J Clin Endocrinol Metab 98(11):4291\u20134299. https:\/\/doi.org\/10.1210\/jc.2013-1804","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"3535_CR51","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1210\/jc.2014-3014","volume":"100","author":"M Salvi","year":"2015","unstructured":"Salvi M, Vannucchi G, Curro N et al (2015) Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves\u2019 orbitopathy: a randomized controlled study. J Clin Endocrinol Metab 100(2):422\u2013431. https:\/\/doi.org\/10.1210\/jc.2014-3014","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"3535_CR52","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.4049\/jimmunol.175.2.1310","volume":"175","author":"B Chen","year":"2005","unstructured":"Chen B, Tsui S, Smith TJ (2005) IL-1 beta induces IL-6 expression in human orbital fibroblasts: identification of an anatomic-site specific phenotypic attribute relevant to thyroid-associated ophthalmopathy. J Immunol 175(2):1310\u20131319. https:\/\/doi.org\/10.4049\/jimmunol.175.2.1310","journal-title":"J Immunol"},{"issue":"1","key":"3535_CR53","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1136\/bjophthalmol-2015-307399","volume":"100","author":"JJ Khong","year":"2016","unstructured":"Khong JJ, McNab AA, Ebeling PR, Craig JE, Selva D (2016) Pathogenesis of thyroid eye disease: review and update on molecular mechanisms. Br J Ophthalmol 100(1):142\u2013150. https:\/\/doi.org\/10.1136\/bjophthalmol-2015-307399","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"3535_CR54","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1097\/ICU.0b013e3283499446","volume":"22","author":"RS Douglas","year":"2011","unstructured":"Douglas RS, Gupta S (2011) The pathophysiology of thyroid eye disease: implications for immunotherapy. Curr Opin Ophthalmol 22(5):385\u2013390. https:\/\/doi.org\/10.1097\/ICU.0b013e3283499446","journal-title":"Curr Opin Ophthalmol"},{"issue":"3","key":"3535_CR55","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/cei.12295","volume":"176","author":"M Mesquida","year":"2014","unstructured":"Mesquida M, Leszczynska A, Llorenc V, Adan A (2014) Interleukin-6 blockade in ocular inflammatory diseases. Clin Exp Immunol 176(3):301\u2013309. https:\/\/doi.org\/10.1111\/cei.12295","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"3535_CR56","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1097\/IOP.0000000000000037","volume":"30","author":"JV Perez-Moreiras","year":"2014","unstructured":"Perez-Moreiras JV, Alvarez-Lopez A, Gomez EC (2014) Treatment of active corticosteroid-resistant graves\u2019 orbitopathy. Ophthalmic Plast Reconstr Surg 30(2):162\u2013167. https:\/\/doi.org\/10.1097\/IOP.0000000000000037","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"3535_CR57","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ajo.2018.07.038","volume":"195","author":"JV Perez-Moreiras","year":"2018","unstructured":"Perez-Moreiras JV, Gomez-Reino JJ, Maneiro JR et al (2018) Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant Graves orbitopathy: a randomized clinical trial. Am J Ophthalmol 195:181\u2013190. https:\/\/doi.org\/10.1016\/j.ajo.2018.07.038","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"3535_CR58","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/s1474-4422(20)30078-8","volume":"19","author":"A Traboulsee","year":"2020","unstructured":"Traboulsee A, Greenberg BM, Bennett JL et al (2020) Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol 19(5):402\u2013412. https:\/\/doi.org\/10.1016\/s1474-4422(20)30078-8","journal-title":"Lancet Neurol"},{"issue":"22","key":"3535_CR59","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","volume":"381","author":"T Yamamura","year":"2019","unstructured":"Yamamura T, Kleiter I, Fujihara K et al (2019) Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med 381(22):2114\u20132124. https:\/\/doi.org\/10.1056\/NEJMoa1901747","journal-title":"N Engl J Med"},{"issue":"8","key":"3535_CR60","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1007\/s10792-023-02679-1","volume":"43","author":"A Musakulova","year":"2023","unstructured":"Musakulova A, Balmukhanova A, Aubakirova A et al (2023) Assessment of the levels of interleukin-17 and interleukin-38 in thyroid-associated ophthalmopathy patients. Int Ophthalmol 43(8):2811\u20132824. https:\/\/doi.org\/10.1007\/s10792-023-02679-1","journal-title":"Int Ophthalmol"},{"issue":"12","key":"3535_CR61","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1089\/thy.2022.0173","volume":"32","author":"YP Hai","year":"2022","unstructured":"Hai YP, Saeed MEM, Ponto KA et al (2022) A multicenter, single-blind, case-control, immunohistochemical study of orbital tissue in thyroid eye disease. Thyroid 32(12):1547\u20131558. https:\/\/doi.org\/10.1089\/thy.2022.0173","journal-title":"Thyroid"},{"key":"3535_CR62","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqad004","author":"M Jiang","year":"2023","unstructured":"Jiang M, Fu Y, Wang P et al (2023) Looking beyond Th17 cells: a role for Th17.1 cells in thyroid-associated ophthalmopathy? Endocrinology. https:\/\/doi.org\/10.1210\/endocr\/bqad004","journal-title":"Endocrinology"},{"key":"3535_CR63","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.16915","author":"E Daud\u00e9n","year":"2024","unstructured":"Daud\u00e9n E, Escario E, Martos-Cabrera L et al (2024) Dose reduction is a feasible strategy in patients with plaque psoriasis who achieve sustained response with secukinumab: a retrospective, multicenter cohort study in daily practice setting. Int J Dermatol. https:\/\/doi.org\/10.1111\/ijd.16915","journal-title":"Int J Dermatol"},{"issue":"1","key":"3535_CR64","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/rheumatology\/kead181","volume":"63","author":"GS Kaeley","year":"2024","unstructured":"Kaeley GS, Schett G, Conaghan PG et al (2024) Enthesitis in patients with psoriatic arthritis treated with secukinumab or adalimumab: a post hoc analysis of the EXCEED study. Rheumatology (Oxford) 63(1):41\u201349. https:\/\/doi.org\/10.1093\/rheumatology\/kead181","journal-title":"Rheumatology (Oxford)"},{"issue":"4 Suppl","key":"3535_CR65","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.1038\/nm1226","volume":"11","author":"M Larch\u00e9","year":"2005","unstructured":"Larch\u00e9 M, Wraith DC (2005) Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat Med 11(4 Suppl):S69-76. https:\/\/doi.org\/10.1038\/nm1226","journal-title":"Nat Med"},{"issue":"2","key":"3535_CR66","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/ni756","volume":"3","author":"SM Anderton","year":"2002","unstructured":"Anderton SM, Viner NJ, Matharu P, Lowrey PA, Wraith DC (2002) Influence of a dominant cryptic epitope on autoimmune T cell tolerance. Nat Immunol 3(2):175\u2013181. https:\/\/doi.org\/10.1038\/ni756","journal-title":"Nat Immunol"},{"issue":"7","key":"3535_CR67","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1089\/thy.2019.0036","volume":"29","author":"SHS Pearce","year":"2019","unstructured":"Pearce SHS, Dayan C, Wraith DC et al (2019) Antigen-specific immunotherapy with thyrotropin receptor peptides in graves\u2019 hyperthyroidism: a Phase I study. Thyroid 29(7):1003\u20131011. https:\/\/doi.org\/10.1089\/thy.2019.0036","journal-title":"Thyroid"},{"issue":"Pt A","key":"3535_CR68","doi-asserted-by":"publisher","first-page":"110873","DOI":"10.1016\/j.intimp.2023.110873","volume":"124","author":"H Duan","year":"2023","unstructured":"Duan H, Jiang Z, Chen L et al (2023) TSHR-based chimeric antigen receptor T cell specifically deplete auto-reactive B lymphocytes for treatment of autoimmune thyroid disease. Int Immunopharmacol 124(Pt A):110873. https:\/\/doi.org\/10.1016\/j.intimp.2023.110873","journal-title":"Int Immunopharmacol"},{"issue":"6","key":"3535_CR69","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1210\/en.2019-00055","volume":"160","author":"CC Krieger","year":"2019","unstructured":"Krieger CC, Boutin A, Jang D et al (2019) Arrestin-\u03b2-1 physically scaffolds TSH and IGF1 receptors to enable crosstalk. Endocrinology 160(6):1468\u20131479","journal-title":"Endocrinology"},{"issue":"1","key":"3535_CR70","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1210\/er.2018-00066","volume":"40","author":"TJ Smith","year":"2019","unstructured":"Smith TJ, Janssen JA (2019) Insulin-like growth factor-I receptor and thyroid-associated ophthalmopathy. Endocr Rev 40(1):236\u2013267","journal-title":"Endocr Rev"},{"issue":"6","key":"3535_CR71","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.4155\/fmc.09.89","volume":"1","author":"MJ Mulvihill","year":"2009","unstructured":"Mulvihill MJ, Cooke A, Rosenfeld-Franklin M et al (2009) Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. Future Med Chem 1(6):1153\u20131171","journal-title":"Future Med Chem"},{"key":"3535_CR72","doi-asserted-by":"publisher","first-page":"1211473","DOI":"10.3389\/fendo.2023.1211473","volume":"14","author":"A Gulbins","year":"2023","unstructured":"Gulbins A, Horstmann M, Daser A et al (2023) Linsitinib, an IGF-1R inhibitor, attenuates disease development and progression in a model of thyroid eye disease. Front Endocrinol (Lausanne) 14:1211473. https:\/\/doi.org\/10.3389\/fendo.2023.1211473","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"18","key":"3535_CR73","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1016\/j.ejca.2010.06.005","volume":"46","author":"B Geoerger","year":"2010","unstructured":"Geoerger B, Brasme J-F, Daudigeos-Dubus E et al (2010) Anti-insulin-like growth factor 1 receptor antibody EM164 (murine AVE1642) exhibits anti-tumour activity alone and in combination with temozolomide against neuroblastoma. Eur J Cancer 46(18):3251\u20133262","journal-title":"Eur J Cancer"},{"issue":"4","key":"3535_CR74","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1910434","volume":"382","author":"RS Douglas","year":"2020","unstructured":"Douglas RS, Kahaly GJ, Patel A et al (2020) Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med 382(4):341\u2013352. https:\/\/doi.org\/10.1056\/NEJMoa1910434","journal-title":"N Engl J Med"},{"issue":"18","key":"3535_CR75","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","volume":"376","author":"TJ Smith","year":"2017","unstructured":"Smith TJ, Kahaly GJ, Ezra DG et al (2017) Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med 376(18):1748\u20131761. https:\/\/doi.org\/10.1056\/NEJMoa1614949","journal-title":"N Engl J Med"},{"issue":"8","key":"3535_CR76","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s40262-021-01003-3","volume":"60","author":"Y Xin","year":"2021","unstructured":"Xin Y, Xu F, Gao Y et al (2021) Pharmacokinetics and exposure-response relationship of teprotumumab, an insulin-like growth factor-1 receptor-blocking antibody, in thyroid eye disease. Clin Pharmacokinet 60(8):1029\u20131040. https:\/\/doi.org\/10.1007\/s40262-021-01003-3","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"3535_CR77","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s40265-020-01287-y","volume":"80","author":"A Markham","year":"2020","unstructured":"Markham A (2020) Teprotumumab: first approval. Drugs 80(5):509\u2013512. https:\/\/doi.org\/10.1007\/s40265-020-01287-y","journal-title":"Drugs"},{"issue":"11","key":"3535_CR78","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/j.ophtha.2021.04.024","volume":"128","author":"BJ Winn","year":"2021","unstructured":"Winn BJ, Kersten RC (2021) Teprotumumab: interpreting the clinical trials in the context of thyroid eye disease pathogenesis and current therapies. Ophthalmology 128(11):1627\u20131651. https:\/\/doi.org\/10.1016\/j.ophtha.2021.04.024","journal-title":"Ophthalmology"},{"key":"3535_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2023.12.001","author":"CJ Hwang","year":"2023","unstructured":"Hwang CJ, Rebollo NP, Mechels KB, Perry JD (2023) Reactivation after teprotumumab treatment for active thyroid eye disease. Am J Ophthalmol. https:\/\/doi.org\/10.1016\/j.ajo.2023.12.001","journal-title":"Am J Ophthalmol"},{"key":"3535_CR80","doi-asserted-by":"crossref","unstructured":"Collins J, Jones L, Snyder M et al (2019) RVT-1401, A novel anti-FcRn monoclonal antibody, is well tolerated in healthy subjects and reduces plasma IgG following subcutaneous or intravenous administration (P5. 2-079). Neurology 92(15)","DOI":"10.1212\/WNL.92.15_supplement.P5.2-079"},{"issue":"2","key":"3535_CR81","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s40120-022-00345-9","volume":"11","author":"C Yan","year":"2022","unstructured":"Yan C, Duan R-S, Yang H et al (2022) Therapeutic effects of batoclimab in Chinese patients with generalized myasthenia gravis: a double-blinded, randomized, placebo-controlled phase II study. Neurol Ther 11(2):815\u2013834","journal-title":"Neurol Ther"},{"issue":"12","key":"3535_CR82","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.1210\/clinem\/dgad381","volume":"108","author":"GJ Kahaly","year":"2023","unstructured":"Kahaly GJ, Dolman PJ, Wolf J et al (2023) Proof-of-concept and randomized, placebo-controlled trials of an FcRn inhibitor, Batoclimab, for thyroid eye disease. J Clin Endocrinol Metab 108(12):3122\u20133134. https:\/\/doi.org\/10.1210\/clinem\/dgad381","journal-title":"J Clin Endocrinol Metab"},{"key":"3535_CR83","doi-asserted-by":"publisher","first-page":"682","DOI":"10.3389\/fimmu.2014.00682","volume":"5","author":"KM Sand","year":"2014","unstructured":"Sand KM, Bern M, Nilsen J, Noordzij HT, Sandlie I, Andersen JT (2014) Unraveling the interaction between FcRn and albumin: opportunities for design of albumin-based therapeutics. Front Immunol 5:682. https:\/\/doi.org\/10.3389\/fimmu.2014.00682","journal-title":"Front Immunol"},{"issue":"3","key":"3535_CR84","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jaci.2020.07.016","volume":"146","author":"HH Peter","year":"2020","unstructured":"Peter HH, Ochs HD, Cunningham-Rundles C et al (2020) Targeting FcRn for immunomodulation: benefits, risks, and practical considerations. J Allergy Clin Immunol 146(3):479-491.e5. https:\/\/doi.org\/10.1016\/j.jaci.2020.07.016","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"3535_CR85","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/ene.15561","volume":"30","author":"Y Wang","year":"2023","unstructured":"Wang Y, Zhong X, Wang H et al (2023) Batoclimab as an add-on therapy in neuromyelitis optica spectrum disorder patients with acute attacks. Eur J Neurol 30(1):195\u2013203. https:\/\/doi.org\/10.1111\/ene.15561","journal-title":"Eur J Neurol"},{"key":"3535_CR86","doi-asserted-by":"publisher","first-page":"1229112","DOI":"10.3389\/fneur.2023.1229112","volume":"14","author":"V Bhandari","year":"2023","unstructured":"Bhandari V, Bril V (2023) FcRN receptor antagonists in the management of myasthenia gravis. Front Neurol 14:1229112. https:\/\/doi.org\/10.3389\/fneur.2023.1229112","journal-title":"Front Neurol"},{"issue":"3","key":"3535_CR87","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3341\/kjo.2024.0031","volume":"38","author":"JW Park","year":"2024","unstructured":"Park JW, Yoon JS (2024) A review of novel medical treatments for thyroid eye disease. Korean J Ophthalmol 38(3):249\u2013259. https:\/\/doi.org\/10.3341\/kjo.2024.0031","journal-title":"Korean J Ophthalmol"},{"issue":"1","key":"3535_CR88","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1055\/s-0037-1598192","volume":"31","author":"TL Braun","year":"2017","unstructured":"Braun TL, Bhadkamkar MA, Jubbal KT, Weber AC, Marx DP (2017) Orbital decompression for thyroid eye disease. Semin Plast Surg 31(1):40\u201345. https:\/\/doi.org\/10.1055\/s-0037-1598192","journal-title":"Semin Plast Surg"},{"issue":"4S Suppl 1","key":"3535_CR89","doi-asserted-by":"publisher","first-page":"S60","DOI":"10.1097\/IOP.0000000000001146","volume":"34","author":"P Saeed","year":"2018","unstructured":"Saeed P, Tavakoli Rad S, Bisschop P (2018) Dysthyroid optic neuropathy. Ophthalmic Plast Reconstr Surg 34(4S Suppl 1):S60\u2013S67. https:\/\/doi.org\/10.1097\/IOP.0000000000001146","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"1","key":"3535_CR90","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/IIO.0000000000000101","volume":"56","author":"AJ Victores","year":"2016","unstructured":"Victores AJ, Takashima M (2016) Thyroid eye disease: optic neuropathy and orbital decompression. Int Ophthalmol Clin Winter 56(1):69\u201379. https:\/\/doi.org\/10.1097\/IIO.0000000000000101","journal-title":"Int Ophthalmol Clin Winter"},{"issue":"1","key":"3535_CR91","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.survophthal.2017.03.007","volume":"63","author":"DB Rootman","year":"2018","unstructured":"Rootman DB (2018) Orbital decompression for thyroid eye disease. Surv Ophthalmol 63(1):86\u2013104. https:\/\/doi.org\/10.1016\/j.survophthal.2017.03.007","journal-title":"Surv Ophthalmol"},{"issue":"5","key":"3535_CR92","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.ophtha.2005.10.060","volume":"113","author":"L Baldeschi","year":"2006","unstructured":"Baldeschi L, Wakelkamp IM, Lindeboom R, Prummel MF, Wiersinga WM (2006) Early versus late orbital decompression in Graves\u2019 orbitopathy: a retrospective study in 125 patients. Ophthalmology 113(5):874\u2013878. https:\/\/doi.org\/10.1016\/j.ophtha.2005.10.060","journal-title":"Ophthalmology"},{"issue":"3","key":"3535_CR93","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.ajo.2007.10.018","volume":"145","author":"L Baldeschi","year":"2008","unstructured":"Baldeschi L, MacAndie K, Koetsier E, Blank LE, Wiersinga WM (2008) The influence of previous orbital irradiation on the outcome of rehabilitative decompression surgery in graves orbitopathy. Am J Ophthalmol 145(3):534\u2013540. https:\/\/doi.org\/10.1016\/j.ajo.2007.10.018","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"3535_CR94","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/s0161-6420(02)01068-0","volume":"109","author":"DO Kikkawa","year":"2002","unstructured":"Kikkawa DO, Pornpanich K, Cruz RC Jr, Levi L, Granet DB (2002) Graded orbital decompression based on severity of proptosis. Ophthalmology 109(7):1219\u20131224. https:\/\/doi.org\/10.1016\/s0161-6420(02)01068-0","journal-title":"Ophthalmology"},{"issue":"3","key":"3535_CR95","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/archotol.1990.01870030039006","volume":"116","author":"DW Kennedy","year":"1990","unstructured":"Kennedy DW, Goodstein ML, Miller NR, Zinreich SJ (1990) Endoscopic transnasal orbital decompression. Arch Otolaryngol Head Neck Surg 116(3):275\u2013282. https:\/\/doi.org\/10.1001\/archotol.1990.01870030039006","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"6","key":"3535_CR96","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1288\/00005537-195706000-00002","volume":"67","author":"TE Walsh","year":"1957","unstructured":"Walsh TE, Ogura JH (1957) Transantral orbital decompression for malignant exophthalmos. Laryngoscope 67(6):544\u2013568. https:\/\/doi.org\/10.1288\/00005537-195706000-00002","journal-title":"Laryngoscope"},{"issue":"2","key":"3535_CR97","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1046\/j.1365-2273.1999.00219.x","volume":"24","author":"SM Graham","year":"1999","unstructured":"Graham SM, Carter KD (1999) Combined-approach orbital decompression for thyroid-related orbitopathy. Clin Otolaryngol Allied Sci 24(2):109\u2013113. https:\/\/doi.org\/10.1046\/j.1365-2273.1999.00219.x","journal-title":"Clin Otolaryngol Allied Sci"},{"issue":"6","key":"3535_CR98","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1097\/00005537-200206000-00009","volume":"112","author":"SM Graham","year":"2002","unstructured":"Graham SM, Thomas RD, Carter KD, Nerad JA (2002) The transcaruncular approach to the medial orbital wall. Laryngoscope 112(6):986\u2013989. https:\/\/doi.org\/10.1097\/00005537-200206000-00009","journal-title":"Laryngoscope"},{"issue":"8 Pt 1","key":"3535_CR99","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1288\/00005537-199408000-00008","volume":"104","author":"R Metson","year":"1994","unstructured":"Metson R, Dallow RL, Shore JW (1994) Endoscopic orbital decompression. Laryngoscope 104(8 Pt 1):950\u2013957. https:\/\/doi.org\/10.1288\/00005537-199408000-00008","journal-title":"Laryngoscope"},{"issue":"5","key":"3535_CR100","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1177\/0194599816630722","volume":"154","author":"WC Yao","year":"2016","unstructured":"Yao WC, Sedaghat AR, Yadav P, Fay A, Metson R (2016) Orbital decompression in the endoscopic age: the modified inferomedial orbital strut. Otolaryngol Head Neck Surg 154(5):963\u2013969. https:\/\/doi.org\/10.1177\/0194599816630722","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"1","key":"3535_CR101","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/MOO.0000000000000326","volume":"25","author":"D Wehrmann","year":"2017","unstructured":"Wehrmann D, Antisdel JL (2017) An update on endoscopic orbital decompression. Curr Opin Otolaryngol Head Neck Surg 25(1):73\u201378. https:\/\/doi.org\/10.1097\/MOO.0000000000000326","journal-title":"Curr Opin Otolaryngol Head Neck Surg"},{"issue":"1","key":"3535_CR102","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/00002341-199203000-00005","volume":"8","author":"RA Goldberg","year":"1992","unstructured":"Goldberg RA, Shorr N, Cohen MS (1992) The medical orbital strut in the prevention of postdecompression dystopia in dysthyroid ophthalmopathy. Ophthalmic Plast Reconstr Surg 8(1):32\u201334. https:\/\/doi.org\/10.1097\/00002341-199203000-00005","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"3","key":"3535_CR103","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/IOP.0000000000000699","volume":"33","author":"CY Wu","year":"2017","unstructured":"Wu CY, Niziol LM, Musch DC, Kahana A (2017) Thyroid-related orbital decompression surgery: a multivariate analysis of risk factors and outcomes. Ophthalmic Plast Reconstr Surg 33(3):189\u2013195. https:\/\/doi.org\/10.1097\/IOP.0000000000000699","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"2","key":"3535_CR104","doi-asserted-by":"publisher","first-page":"283","DOI":"10.2147\/opth.s2416","volume":"2","author":"S Sellari-Franceschini","year":"2008","unstructured":"Sellari-Franceschini S, Muscatello L, Seccia V et al (2008) Reasons for revision surgery after orbital decompression for Graves\u2019 orbitopathy. Clin Ophthalmol 2(2):283\u2013290. https:\/\/doi.org\/10.2147\/opth.s2416","journal-title":"Clin Ophthalmol"},{"issue":"6","key":"3535_CR105","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1002\/lary.20213","volume":"119","author":"SC Leong","year":"2009","unstructured":"Leong SC, Karkos PD, Macewen CJ, White PS (2009) A systematic review of outcomes following surgical decompression for dysthyroid orbitopathy. Laryngoscope 119(6):1106\u20131115. https:\/\/doi.org\/10.1002\/lary.20213","journal-title":"Laryngoscope"},{"key":"3535_CR106","doi-asserted-by":"publisher","unstructured":"European Group on Graves O, Mourits MP, Bijl H et al (2009) Outcome of orbital decompression for disfiguring proptosis in patients with Graves' orbitopathy using various surgical procedures. Br J Ophthalmol 93(11):1518\u20131523. https:\/\/doi.org\/10.1136\/bjo.2008.149302","DOI":"10.1136\/bjo.2008.149302"},{"issue":"1","key":"3535_CR107","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jcms.2014.10.008","volume":"43","author":"EM Kang","year":"2015","unstructured":"Kang EM, Yoon JS (2015) Clinical and radiological characteristics of Graves\u2019 orbitopathy patients showing spontaneous decompression. J Craniomaxillofac Surg 43(1):48\u201352. https:\/\/doi.org\/10.1016\/j.jcms.2014.10.008","journal-title":"J Craniomaxillofac Surg"},{"issue":"4","key":"3535_CR108","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1001\/jamaoto.2014.3659","volume":"141","author":"S Thapa","year":"2015","unstructured":"Thapa S, Gupta AK, Gupta A, Gupta V, Dutta P, Virk RS (2015) Proptosis reduction by clinical vs radiological modalities and medial vs inferomedial approaches: comparison following endoscopic transnasal orbital decompression in patients with dysthyroid orbitopathy. JAMA Otolaryngol Head Neck Surg 141(4):329\u2013334. https:\/\/doi.org\/10.1001\/jamaoto.2014.3659","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"6","key":"3535_CR109","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.amjoto.2015.06.005","volume":"36","author":"BA Schiff","year":"2015","unstructured":"Schiff BA, McMullen CP, Farinhas J et al (2015) Use of computed tomography to assess volume change after endoscopic orbital decompression for Graves\u2019 ophthalmopathy. Am J Otolaryngol 36(6):729\u2013735. https:\/\/doi.org\/10.1016\/j.amjoto.2015.06.005","journal-title":"Am J Otolaryngol"},{"issue":"5_suppl","key":"3535_CR110","doi-asserted-by":"publisher","first-page":"443S","DOI":"10.1177\/0145561319885803","volume":"100","author":"S Mattheis","year":"2021","unstructured":"Mattheis S, Schluter A, Stahr K et al (2021) First use of a new robotic endoscope guiding system in endoscopic orbital decompression. Ear Nose Throat J 100(5_suppl):443S-448S. https:\/\/doi.org\/10.1177\/0145561319885803","journal-title":"Ear Nose Throat J"},{"issue":"6","key":"3535_CR111","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.jaapos.2012.08.010","volume":"16","author":"NJ Volpe","year":"2012","unstructured":"Volpe NJ, Mirza-George N, Binenbaum G (2012) Surgical management of vertical ocular misalignment in thyroid eye disease using an adjustable suture technique. J aapos 16(6):518\u2013522. https:\/\/doi.org\/10.1016\/j.jaapos.2012.08.010","journal-title":"J aapos"},{"issue":"6","key":"3535_CR112","doi-asserted-by":"publisher","first-page":"3679","DOI":"10.1177\/11206721221083836","volume":"32","author":"MP Laezza","year":"2022","unstructured":"Laezza MP, Concilio M, Giordano M, Lanni V, Iuliano A, Strianese D (2022) Outcomes and risk factors of surgical management of thyroid eye disease-related diplopia. Eur J Ophthalmol 32(6):3679\u20133684. https:\/\/doi.org\/10.1177\/11206721221083836","journal-title":"Eur J Ophthalmol"},{"issue":"1","key":"3535_CR113","first-page":"36","volume":"119","author":"SM Couch","year":"2022","unstructured":"Couch SM (2022) Teprotumumab (Tepezza) for thyroid eye disease. Mo Med 119(1):36\u201341","journal-title":"Mo Med"},{"issue":"6","key":"3535_CR114","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1097\/icu.0000000000000997","volume":"34","author":"PS Subramanian","year":"2023","unstructured":"Subramanian PS, Cho RI, Kahana A (2023) Efficacy of teprotumumab therapy in patients with long-duration thyroid eye disease. Curr Opin Ophthalmol 34(6):487\u2013492. https:\/\/doi.org\/10.1097\/icu.0000000000000997","journal-title":"Curr Opin Ophthalmol"},{"issue":"2","key":"3535_CR115","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1089\/thy.2021.0411","volume":"32","author":"T Woo","year":"2022","unstructured":"Woo T, Li C, Ganesananthan S et al (2022) The effect of ophthalmic surgery for Graves\u2019 orbitopathy on quality of life: a systematic review and meta-analysis. Thyroid 32(2):177\u2013187. https:\/\/doi.org\/10.1089\/thy.2021.0411","journal-title":"Thyroid"},{"issue":"4","key":"3535_CR116","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1097\/iop.0000000000002611","volume":"40","author":"LO Dallalzadeh","year":"2024","unstructured":"Dallalzadeh LO, Villatoro GA, Chen L et al (2024) Teprotumumab for thyroid eye disease-related strabismus. Ophthalmic Plast Reconstr Surg 40(4):434\u2013439. https:\/\/doi.org\/10.1097\/iop.0000000000002611","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"3535_CR117","doi-asserted-by":"publisher","DOI":"10.1097\/iop.0000000000002707","author":"EM Al-Sharif","year":"2024","unstructured":"Al-Sharif EM, Zhou J, Shoji MK et al (2024) Effects of teprotumumab on eyelid retraction in thyroid eye disease. Ophthalmic Plast Reconstr Surg. https:\/\/doi.org\/10.1097\/iop.0000000000002707","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"3","key":"3535_CR118","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1097\/iop.0000000000002563","volume":"40","author":"S Hubschman","year":"2024","unstructured":"Hubschman S, Sojitra B, Ghiam S et al (2024) Teprotumumab and orbital decompression for the management of proptosis in patients with thyroid eye disease. Ophthalmic Plast Reconstr Surg 40(3):270\u2013275. https:\/\/doi.org\/10.1097\/iop.0000000000002563","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"3535_CR119","doi-asserted-by":"publisher","DOI":"10.1080\/01676830.2023.2282509","author":"MAJ Ting","year":"2023","unstructured":"Ting MAJ, Topilow NJ, Ediriwickrema LS et al (2023) A comparison of proptosis reduction with teprotumumab versus surgical decompression based on fat-to-muscle ratio in thyroid eye disease. Orbit. https:\/\/doi.org\/10.1080\/01676830.2023.2282509","journal-title":"Orbit"},{"issue":"1","key":"3535_CR120","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1016\/j.jcjo.2024.06.003","volume":"60","author":"NJ Topilow","year":"2025","unstructured":"Topilow NJ, Penteado RC, Ting M et al (2025) Orbital decompression following treatment with teprotumumab for thyroid eye disease. Can J Ophthalmol 60(1):e59\u2013e64. https:\/\/doi.org\/10.1016\/j.jcjo.2024.06.003","journal-title":"Can J Ophthalmol"},{"issue":"4","key":"3535_CR121","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/iop.0000000000002315","volume":"39","author":"NF Xavier","year":"2023","unstructured":"Xavier NF, Lucena DT, Cruz AAV (2023) Monoclonal antibodies for the treatment of graves orbitopathy: precision medicine? Ophthalmic Plast Reconstr Surg 39(4):307\u2013315. https:\/\/doi.org\/10.1097\/iop.0000000000002315","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"1","key":"3535_CR122","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1097\/iop.0000000000002483","volume":"40","author":"RZ Silkiss","year":"2024","unstructured":"Silkiss RZ (2024) The use of polypharmacy to treat thyroid eye disease. Ophthalmic Plast Reconstr Surg 40(1):116. https:\/\/doi.org\/10.1097\/iop.0000000000002483","journal-title":"Ophthalmic Plast Reconstr Surg"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-025-03535-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-025-03535-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-025-03535-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T18:04:47Z","timestamp":1766167487000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-025-03535-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,3]]},"references-count":122,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3535"],"URL":"https:\/\/doi.org\/10.1007\/s10792-025-03535-0","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,3]]},"assertion":[{"value":"22 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no financial or conflict of interest in any material discussed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"160"}}